Condition hub
Living with inflammatory myositis
What myositis is doing, and why weakness counts for more than pain.
Weakness, not pain
Your immune system damages muscle, and what that produces is weakness rather than pain, mostly in the muscles closest to the trunk. People mention pain readily and explain weakness away, which is why describing what you can no longer do gets you further than rating how bad it feels.
It builds, and it is not one disease
This comes on over weeks to months rather than all at once, and it covers several separate conditions with different antibodies behind them. Which one you have decides which organs get watched and how urgently the treatment moves.
Exercise doesn't raise your CK
A review of nineteen studies and 298 patients found exercise improving strength by 0.61 standard deviations and fitness by 0.82, with no difference in creatine phosphokinase between the exercise and control groups and no flares recorded anywhere in it.1
One subtype moves fast
Anti-MDA5 dermatomyositis brings a lung risk that can move in weeks rather than months, and that is why knowing your antibody profile counts. New or worse breathlessness needs prompt attention here whatever your last set of tests said.
The four-step plan, applied to myositis.
Get the right diagnosis
Muscle enzymes, an antibody panel, and sometimes imaging or a muscle biopsy. Which antibody you have is most of what decides how closely your lungs get watched, so ask which one you have if you have not been told.
Myositis and labs →Clean up your food
Trouble swallowing is the real food problem here, and it has treatment. Enough protein alongside your training is the other half, because muscle is what you are trying to keep.
Myositis and diet →Detox your daily life
Silica and solvents have been studied in several other autoimmune diseases and never measured in this one. Workplace dust is still worth telling your team about, for your lungs more than for your muscles.
Myositis and environment →Build a stronger body
Resistance work is the part with the evidence, and it did not raise disease activity or creatine kinase in the trials that measured both. Hard training in stable disease has been tested and came out safe in it.
Myositis and exercise →
Pro tip
If you find yourself pulling on a bannister or pushing off the arms of a chair, say so at your appointment, because those workarounds are often what other people notice first. Describing the task you can no longer do tells your team more than any rating of how bad the weakness feels.
The biology behind it, subtype by subtype
The antibody behind your diagnosis is not a label so much as a different disease wearing the same name, and two subtypes make that plainest. One is triggered by a drug rather than by nothing at all: a statin can switch on an antibody against an enzyme called HMGCR, and in a cohort of 750 people tested at a myositis center, 45 had that antibody. Among the ones over fifty who had it, the great majority, better than nine in ten, had taken a statin at some point. Muscle cells that are busy repairing themselves make even more of the target protein, which is one reason the antibody response can keep going after the statin is stopped.
Inclusion body myositis is the other subtype worth knowing apart from the rest, because it breaks the plan this page gives everyone else. It tends to start later in life, weakens the hands and the front of the thigh in a pattern the others don't share, and does not reliably respond to the immune-suppressing drugs that help the other subtypes. A modern trial tested a targeted drug against placebo in 44 people with inclusion body myositis over a full year and found no difference in the main strength measure the trial was built to detect. Exercise is the treatment with evidence behind it here, not a fallback after drugs fail.
Weakness, not pain
What sets myositis apart from most muscle problems is that the main symptom is weakness rather than pain, and that distinction counts. The weakness usually reaches the muscles closest to the trunk first, so climbing stairs is the task people notice, along with standing up from a low chair and lifting your arms to wash your hair. It builds over weeks to months rather than all at once.
Some people ache as well, and the absence of aching doesn't argue against the diagnosis. If you find yourself compensating, say so, because pulling on a bannister and pushing off the arms of a chair both count. Those workarounds are often what other people notice first.
What exercise does, including to creatine kinase
Lungs, and why the antibody counts
Lung disease is the complication that most affects the outcome here, and the risk isn't spread evenly across the group. Anti-MDA5 dermatomyositis brings a lung risk that can move in weeks rather than months, and spotting who is at risk lets treatment move at that speed too. Knowing your own antibody profile is genuinely useful for that reason.
The blood signs that predict fast progression are differences between groups rather than thresholds anyone can apply to your own result. They guide how closely you get watched, and they give you no number to act on. New or worse breathlessness needs prompt attention whatever your tests say.
Common misconceptions.
Myth. Myositis is just one disease.
Reality. It's a family of four distinct entities (PM, DM, IMNM, IBM) with different mechanisms, different antibodies, and different treatments. Calling them all 'myositis' without subtyping leads to wrong treatment. The myositis-specific antibody panel changes management.
In plain words. Myositis is four different diseases sharing one word. They have different causes and different treatments. The antibody panel tells you which one you have, and that changes your care.
Myth. Steroids will fix it.
Reality. PM and DM often respond to steroids initially, but most patients need a steroid-sparing agent (methotrexate, mycophenolate, rituximab, IVIG). IMNM is often steroid-refractory and requires IVIG plus immunosuppression. IBM doesn't respond to immunosuppression at all, exercise is the foundation.
In plain words. Steroids often work at first. Most people then need a second drug. One type barely answers steroids at all. Another doesn't answer immune drugs at all, and for that one exercise is the main treatment.
Myth. Exercise is dangerous when your creatine kinase is elevated.
Reality. A trial of 32 people with stable myositis put them through 16 weeks of resistance training loaded at ten repetitions to failure. Strength, function, and quality of life all improved, and the training group showed no rise in creatine kinase and no disease flares. That's a real trial rather than a reassurance, and it's the reason exercise sits in this page's plan rather than a caution against it.
In plain words. A real trial tested this directly: 32 people, 16 weeks, working close to failure. Creatine kinase didn't rise and no one flared. Strength and quality of life both improved instead.
When to see a rheumatologist.
See a rheumatologist if you have:
- Progressive proximal muscle weakness (difficulty climbing stairs, rising from a chair, lifting arms overhead)
- Elevated CK on a routine lab
- Characteristic dermatomyositis skin findings (Gottron's papules, heliotrope rash, V-sign)
- Unexplained ILD with proximal weakness
- New dysphagia plus muscle weakness
- Statin myopathy that doesn't resolve with statin discontinuation
- Mechanic's hands (cracked, fissured fingertips)
Weakness in the muscles closest to the trunk is the pattern here, so climbing stairs, standing up from a low chair, and lifting your arms to wash your hair are the tasks worth naming. Trouble swallowing and new breathlessness are the two that need mentioning promptly instead of saving for a routine visit.
References.
- da Silva BISL; Dos Santos BRJ; Carneiro JA et al. Physical exercise for dermatomyositis and polymyositis: a systematic review and meta-analysis. Clinical rheumatology. 2022;41:2635-2646. 10.1007/s10067-022-06281-1SR + MA
- Jensen KY; Aagaard P; Suetta C et al. High-intensity resistance training improves quality of life, muscle endurance and strength in patients with myositis: a randomised controlled trial. Rheumatology international. 2024;44:1909-1921. 10.1007/s00296-024-05698-yRCT
- Jensen KY; Aagaard P; Suetta C et al. High-intensity resistance training in patients with myositis - 1-year follow-up on a randomised controlled trial. Rheumatology international. 2025;45:104. 10.1007/s00296-025-05858-8RCT follow-up
- Liu T; Ji X; Wei Y et al. Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis. Rheumatology (Oxford, England). 2026;65. 10.1093/rheumatology/keag311Systematic review and meta-analysis of 27 cohorts
- Mammen AL; Chung T; Christopher-Stine L et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis & Rheumatism. 2011;63:713-721. 10.1002/art.30156Laboratory identification of the anti-HMGCR autoantigen plus a screened cohort of 750 myopathy patients at the Johns Hopkins Myositis Center
- Benveniste O; Hogrel JY; Belin L et al. Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatology. 2021;3:e40-e48. 10.1016/S2665-9913(20)30280-0Phase 2b randomized
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.